Jasper Therapeutics Inc. (JSPRW)
Jasper Therapeutics Statistics
Share Statistics
Jasper Therapeutics has 15.02M shares outstanding. The number of shares has increased by -99.12% in one year.
| Shares Outstanding | 15.02M |
| Shares Change (YoY) | -99.12% |
| Shares Change (QoQ) | 0.14% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 431 |
| FTD / Avg. Volume | 5.69% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -4.38 and the forward PE ratio is null. Jasper Therapeutics's PEG ratio is 0.21.
| PE Ratio | -4.38 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | 1 |
| PB Ratio | 5.06 |
| P/FCF Ratio | -4.94 |
| PEG Ratio | 0.21 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Jasper Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.98, with a Debt / Equity ratio of 0.03.
| Current Ratio | 4.98 |
| Quick Ratio | 4.98 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | -0.03 |
| Debt / FCF | -0.03 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,113,578.12 |
| Employee Count | 64 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -72.76M |
| Effective Tax Rate | 100% |
Stock Price Statistics
The stock price has increased by -49.37% in the last 52 weeks. The beta is 2.56, so Jasper Therapeutics's price volatility has been higher than the market average.
| Beta | 2.56 |
| 52-Week Price Change | -49.37% |
| 50-Day Moving Average | 0.14 |
| 200-Day Moving Average | 0.19 |
| Relative Strength Index (RSI) | 34.1 |
| Average Volume (20 Days) | 7,581 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -76.24M |
| Net Income | -71.27M |
| EBITDA | -71.39M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -4.89 |
Balance Sheet
The company has 71.64M in cash and 1.81M in debt, giving a net cash position of 69.82M.
| Cash & Cash Equivalents | 71.64M |
| Total Debt | 1.81M |
| Net Cash | 69.82M |
| Retained Earnings | -240.87M |
| Total Assets | 79.9M |
| Working Capital | 60.57M |
Cash Flow
In the last 12 months, operating cash flow was -62.6M and capital expenditures -552K, giving a free cash flow of -63.15M.
| Operating Cash Flow | -62.6M |
| Capital Expenditures | -552K |
| Free Cash Flow | -63.15M |
| FCF Per Share | -4.33 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
JSPRW does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for JSPRW.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -6.42 |
| Piotroski F-Score | 2 |